Encevis: Automated EEG Analysis for Epilepsy and Intensive Care

Overview: How Encevis’s AI-Enabled Neurotechnology Platform Supports EEG Analysis in Epilepsy and Intensive Care

Encevis is an AI-enabled neurotechnology software suite that automates aspects of EEG analysis, supporting the detection and review of seizure activity, epileptiform spikes and changes in brain function. It addresses the difficulty of examining lengthy recordings, where relevant events can be dispersed across hours of data and obscured by artefacts. Its tools bring automated event detection, visual summaries and source localisation into a connected EEG review workflow.

The software applies automated signal-analysis algorithms to identify candidate events, reduce artefacts and summarise activity over time. EEG trending, amplitude-integrated displays and burst-suppression measures provide complementary views of recordings, while source localisation estimates the origins of spikes and seizures. These functions support interpretation rather than replace it: automated detections and processed signals still require assessment alongside the original EEG and clinical context.

Encevis can operate during bedside recording or support later review, with compatibility across multiple EEG file formats and integration into several manufacturers’ systems. Two practical benefits are directing attention to potentially relevant events and presenting long recordings as trends, helping organise review without requiring every segment to be approached identically. Support for the DICOM neurophysiology standard also provides an interoperability option. Actual review-time savings and diagnostic benefit depend on recording quality, configuration and the workflow in which the software is used.

Last checked on 16 October 2026: AIT’s August 2026 update reports AI-based sleep staging, paediatric seizure-detection development and further work on subcutaneous EEG analysis, although release dates and availability are not specified for all capabilities.

What is Encevis?

Encevis is an AI-enabled neurotechnology software suite developed by AIT Austrian Institute of Technology for automated EEG analysis, including seizure and spike detection, artefact reduction, source localisation and trend visualisation. It supports hospital neurology and intensive-care teams, clinical neurophysiology services and researchers through bedside monitoring and retrospective EEG review. Its technical approach combines automated analysis with an EEG viewer supporting multiple manufacturers’ file formats and the DICOM neurophysiology standard, providing decision support rather than autonomous diagnosis.

Intended Use and Limitations

• Encevis is developed by AIT Austrian Institute of Technology, providing an identifiable institutional manufacturer rather than an undisclosed software supplier.

• Encevis 2.1 has FDA 510(k) clearance under K240993 for specified EEG review and analysis functions; clearance should not be extended to every later version or research capability.

• The FDA-cleared seizure-detection component marks previously acquired adult EEG segments that may represent seizures; qualified practitioners must exercise professional judgement.

• AIT’s official Encevis page provides an MDR certificate and an ISO 13485 certificate; buyers should verify their current validity, scope and applicability to the supplied configuration.

• The CE-version user manual states that Encevis must not be used for real-time surveillance because displayed patterns may be delayed by several minutes, an important safety boundary.

• AIT reports a research contract with UNEEG Medical to develop seizure detection for subcutaneous EEG; this does not establish that the functionality is included in every commercial version.

• A 2025 comparative study found improved seizure-detection sensitivity but a higher false-positive rate for the evaluated Encevis version, reinforcing the need for specialist review.

• Published DICOM implementation work demonstrated archiving and retrieval of long-term EEG recordings using the Encevis viewer, supporting interoperability evidence rather than diagnostic-performance claims.

• AIT reports Austrian Research Promotion Agency and European Union support for Encevis development; this is research backing, not a clinical endorsement.